A Phase 1/2 interventional study of LY2940680 and Carboplatin in Small Cell Lung Carcinoma, sponsored by Eli Lilly and Company. Terminated at 14 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-28.
Sponsored by Eli Lilly and Company · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Small Cell Lung Carcinoma by Eli Lilly and Company — none open to participants now, 1 under way, none of them phase 3. Small Cell Lung Carcinoma · Eli Lilly and Company.
Among the 12 studies in Small Cell Lung Carcinoma by Eli Lilly and Company, this one is the 8th largest by enrollment, is the only one that started in 2013, is one of 3 in phase 1/2, and was the 8th registered.
1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.
Browse Small Cell Lung Carcinoma studies →None of the 12 studies in Small Cell Lung Carcinoma by Eli Lilly and Company is open now. The open studies under Small Cell Lung Carcinoma, anywhere →
Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 2
First in 1998; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 56 across 1,077 interventional studies indexed under Small Cell Lung Carcinoma.
Median enrollment 56 across the 12 interventional studies. Of the 11 that completed or were terminated, 9 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Small Cell Lung Carcinoma by Eli Lilly and Company, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to find a recommended dose of LY2940680 that can be safely given in combination with etoposide and carboplatin followed by LY2940680 alone in participants with extensive-disease small cell lung cancer. The study will also compare progression-free survival in participants who are administered etoposide, carboplatin and LY2940680 followed by LY2940680 alone versus etoposide, carboplatin, and placebo followed by placebo alone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adequate organ function including the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phase 1b Dose Escalation: Cycles 1-6 (21 day cycles) LY2940680 administered orally, once daily at escalating doses (100 milligrams \[mg\] up to 400 mg) in combination with etoposide (E) 100 milligram per square meter (mg/m\^2) administered by intravenous (IV) infusion on days 1, 2, 3 of each cycle and carboplatin (C) Area Under the Curve \[AUC\] 5 (mg•min/mL) administered by IV infusion on day 1 each cycle. Phase 1b Maintenance: Cycles 7+ (21 day cycles) LY2940680 administered orally, once daily at the same dose as induction. Participants receiving benefit may continue until disease progression, unacceptable toxicity, or discontinuation.
Drug: LY2940680 · Drug: Carboplatin · Drug: Etoposide
Induction: Cycles 1-6 (21 day cycles) Placebo administered orally once daily in combination with etoposide 100 mg/m2 administered by IV infusion on days 1, 2, 3 of each cycle and carboplatin AUC 5 administered by IV infusion on day 1 each cycle. Maintenance: Cycles 7+ (21 day cycles) Placebo administered orally once daily. Participants receiving benefit may continue until disease progression, unacceptable toxicity, or discontinuation.
Drug: Carboplatin · Drug: Etoposide · Drug: Placebo
Induction: Cycles 1-6 (21 day cycles) LY2940680 (dose to be determined in Phase 1b portion) administered orally once daily in combination with etoposide 100 mg/m\^2 administered by IV infusion on days 1, 2, 3 of each cycle and carboplatin AUC 5 administered by IV infusion on day 1 each cycle. Maintenance: Cycles 7+ (21 day cycles). LY2940680 (dose to be determined in Phase 1 portion) administered orally once daily.
Drug: LY2940680 · Drug: Carboplatin · Drug: Etoposide
Administered orally
Administered IV
Administered IV
Administered orally
Phase 1b: Recommended Phase 2 Dose of LY2940680: Maximum Tolerated Dose (MTD)
MTD was defined as the highest tested dose that has \<33% probability of causing a dose-limiting toxicity(DLT). DLT was defined as an AE during Cycle 1 that is possibly related to the study drug and fulfills any one of the following criterion using the National Cancer Institute(NCI) Common Terminology Criteria for Adverse Events(CTCAE),version 4.0:Grade 3 non-hematological toxicity except nausea, vomiting, constipation, diarrhea, fatigue, or anorexia that is manageable with appropriate care,transient(i.e., ≤5 days) Grade 3 elevations of alanine aminotransferase(ALT) and/or aspartate aminotransferase(AST), without evidence of other hepatic injury, in the setting of preexisting hepatic metastasis, ≥Grade 3 thrombocytopenia with bleeding or Grade 4 thrombocytopenia of any duration,CTCAE Grade 4 hematological toxicity of \>5 days duration and any febrile neutropenia. any other significant toxicity deemed by the primary investigator and Lilly clinical research personnel to be dose-limiting.
Time frame: Baseline to Completion of the Phase 1b (Up To 12 Months)
Phase 2: Progression-Free Survival
Time frame: Randomization to Measured Progressive Disease or Death of Any Cause (Estimated as 18 Months)
Phase 1b and 2: Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2940680, LSN3185556 at the Recommended Dose
Time frame: Cycle (C)1 Day (D) 1:Predose,0.5 ,1, 2, 4, 6, 8h; C2 D1:Pr,0.5,1,2,4,6,8 hours
Phase 1b and 2: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Carboplatin and Etoposide at the Recommended Dose
Time frame: Cycle (C)1 Day (D) 1:Predose,0.5 ,1, 2, 4, 6, 8h; C2 D1:Pr,0.5,1,2,4,6,8 hours
Phase 1b and 2: Pharmacokinetics: Area Under the Curve ( AUC₀-₂₄) for LY2940680 and LSN3185556 at the Recommended Dose
Time frame: Cycle (C)1 Day (D) 1:Predose,0.5 ,1, 2, 4, 6, 8h; C2 D1:Pr,0.5,1,2,4,6,8 hours
Phase 1b and 2: Pharmacokinetics: Area Under the Curve ( AUC₀-₂₄) for Etoposide and as AUC₀-₆ for Carboplatin at the Recommended Dose
Time frame: Cycle (C)1 Day (D) 1:Predose,0.5 ,1, 2, 4, 6, 8h; C2 D1:Pr,0.5,1,2,4,6,8 hours
Phase 1b: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR])
ORR was defined as the percentage of all randomized participants with the best overall response of PR or CR using Response Evaluation Criteria in Solid Tumors (RECIST v1.1). CR is the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Tumor marker results must have normalized. PR is at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters.
Time frame: Baseline to Study Completion Up to 39 Months
Phase 1b: Percentage Inhibition of Expression Levels of Gli1 in Skin Cells
The gene expression data (Gli1) was normalized and the level of percentage of Gli1 inhibition post treatment was calculated.
Time frame: Baseline, Cycle 2 Day 1, Cycle 7 Day 1
Phase 2: Overall Survival
Time frame: Randomization to Study Completion (Estimated as 38 Months)
Phase 2: Percent Change in Tumor Size (CTS)
Time frame: Randomization to End of Cycle 2 (Estimated as 24 Months)
Phase 2: Number of Participants With a Complete or Partial Tumor Response (Overall Response Rate)
Time frame: Randomization to Study Completion (Estimated as 38 Months)
Phase 1b and 2: Pharmacokinetics: Time to Maximal Concentration (Tmax) of LY2940680 andLSN3185556 at the Recommended Dose
Time frame: Cycle (C)1 Day (D) 1:Predose,0.5 ,1, 2, 4, 6, 8h; C2 D1:Pr,0.5,1,2,4,6,8 hours
Phase 1b and 2: Pharmacokinetics: Time to Maximal Concentration (Tmax) of Carboplatin and Etoposide at the Recommended Dose
Time frame: Cycle (C)1 Day (D) 1:Predose,0.5 ,1, 2, 4, 6, 8h; C2 D1:Pr,0.5,1,2,4,6,8 hours
| Milestone | Phase 1b: 100 mg LY2940680 + C + E | Phase 1b: 200 mg LY2940680 + C + E | Phase 1B: 400 mg LY2940680 + C + E |
|---|---|---|---|
| Started | 6 | 6 | 14 |
| Received at least one dose of study drug | 6 | 6 | 14 |
| Completed | 6 | 6 | 14 |
| Not completed | 0 | 0 | 0 |
MTD was defined as the highest tested dose that has \<33% probability of causing a dose-limiting toxicity(DLT). DLT was defined as an AE during Cycle 1 that is possibly related to the study drug and fulfills any one of the following criterion using the National Cancer Institute(NCI) Common Terminology Criteria for Adverse Events(CTCAE),version 4.0:Grade 3 non-hematological toxicity except nausea, vomiting, constipation, diarrhea, fatigue, or anorexia that is manageable with appropriate care,transient(i.e., ≤5 days) Grade 3 elevations of alanine aminotransferase(ALT) and/or aspartate aminotransferase(AST), without evidence of other hepatic injury, in the setting of preexisting hepatic metastasis, ≥Grade 3 thrombocytopenia with bleeding or Grade 4 thrombocytopenia of any duration,CTCAE Grade 4 hematological toxicity of \>5 days duration and any febrile neutropenia. any other significant toxicity deemed by the primary investigator and Lilly clinical research personnel to be dose-limiting.
| milligrams (mg) | Phase 1b |
|---|---|
| Phase 1b: Recommended Phase 2 Dose of LY2940680: Maximum Tolerated Dose (MTD) | 400 |
No measurements were reported for this outcome.
| microgram per milliliter (µg/mL) | Phase 1b: 100 mg LY2940680 + C + E | Phase 1b: 200 mg LY2940680 + C + E | Phase 1B: 400 mg LY2940680 + C + E |
|---|---|---|---|
| LY2940680 Cycle 1, Day 1 | 0.491 ± 64 | 1.01 ± 36 | 1.56 ± 35 |
| LY2940680 Cycle 2, Day 1 | 0.578 ± 71 | 1.16 ± 66 | 3.29 ± 33 |
| LSN3185556 Cycle 1, Day 1 | 0.444 ± 33 | 0.737 ± 138 | 1.75 ± 47 |
| LSN3185556 Cycle 2, Day 1 | 1.6 ± 35 | 2.1 ± 90 | 6 ± 59 |
| microgram per milliliter (µg/mL) | Phase 1b: LY2940680 + C + E |
|---|---|
| Total Carboplatin Cycle 1, Day 1 | 16.7 ± 33 |
| Total Carboplatin Cycle 2, Day 1 | 13.1 ± 42 |
| Etoposide Cycle 1, Day 1 | 20.9 ± 18 |
| Etoposide Cycle 2, Day 1 | 18.4 ± 28 |
| Hour*microgram per milliliter (h.µg/mL) | Phase 1b: 100 mg LY2940680 + C+ E | Phase 1b: 200 mg LY2940680 + C+ E | Phase 1b: 400 mg LY2940680 + C+ E |
|---|---|---|---|
| LY2940680 Cycle 1, Day 1 | 6.34 ± 57 | 8.96 ± 39 | 15.9 ± 27 |
| LY2940680 Cycle 2, Day 1 | 7.86 ± 67 | 15.5 ± 64 | 37.6 ± 43 |
| LSN3185556 Cycle 1, Day 1 | 7.23 ± 49 | 16.2 ± 67 | 26 ± 37 |
| LSN3185556 Cycle 2, Day 1 | 22.7 ± 58 | 31.1 ± 111 | 92.5 ± 72 |
| Hour*microgram per milliliter (h.µg/mL) | Phase 1b: LY2940680 + C+ E |
|---|---|
| Total Carboplatin Cycle 1, Day 1 | 37.2 ± 23 |
| Total Carboplatin Cycle 2, Day 1 | 32.0 ± 25 |
| Etoposide Cycle 1, Day 1 | 104 ± 22 |
| Etoposide Cycle 2, Day 1 | 96.1 ± 20 |
ORR was defined as the percentage of all randomized participants with the best overall response of PR or CR using Response Evaluation Criteria in Solid Tumors (RECIST v1.1). CR is the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Tumor marker results must have normalized. PR is at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Phase 1b: 100 mg LY2940680 + C+ E | Phase 1b: 200 mg LY2940680 + C+ E | Phase 1b: 400 mg LY2940680 + C+ E |
|---|---|---|---|
| Phase 1b: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR]) | 50 (16.4 to 83.6) | 50 (16.4 to 83.6) | 57.1 (35.4 to 78.9) |
The gene expression data (Gli1) was normalized and the level of percentage of Gli1 inhibition post treatment was calculated.
| Percentage of Gli 1 Inhibition | Phase 1b: 100 mg LY2940680 | Phase 1b: 200 mg LY2940680 | Phase 1b: 400 mg LY2940680 |
|---|---|---|---|
| Phase 1b: Percentage Inhibition of Expression Levels of Gli1 in Skin Cells | 94.7 (75.9 to 94.9) | 95.1 (94.5 to 97.2) | 94.8 (90.7 to 97.3) |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
| Hour (h) | Phase 1b: 100 mg LY2940680 + C+ E | Phase 1b: 200 mg LY2940680 + C+ E | Phase 1b: 400 mg LY2940680 + C+ E |
|---|---|---|---|
| LY2940680 Cycle 1, Day 1 | 2.05 (1 to 3.98) | 2.01 (1.03 to 2.05) | 1.51 (0.5 to 6) |
| LY2940680 Cycle 2, Day 1 | 2.96 (0.08 to 5.83) | 4 (1.88 to 4.08) | 1 (0.5 to 6) |
| LSN3185556 Cycle 1, Day 2 | 6.14 (2 to 24.03) | 5.87 (2.07 to 24.97) | 6 (2.05 to 24) |
| LSN3185556 Cycle 2, Day 2 | 2.3 (0 to 4) | 4.08 (4 to 23.83) | 2.21 (0.5 to 6) |
| Hour (h) | Phase 1b: LY2940680 + C+ E |
|---|---|
| Total Carboplatin Cycle 1, Day 1 | 0.5 (0.42 to 1.08) |
| Total Carboplatin Cycle 2, Day 1 | 0.5 (0.42 to 1.05) |
| Etoposide Cycle 1, Day 1 | 0.96 (0.48 to 1.5) |
| Etoposide Cycle 2 ,Day 1 | 0.99 (0.33 to 1.17) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1b: 100 mg LY2940680 + C + E | — | 3/6 (50%) | 6/6 (100%) |
| Phase 1b: 200 mg LY2940680 + C + E | — | 6/6 (100%) | 6/6 (100%) |
| Phase 1b: 400 mg LY2940680 + C + E | — | 8/14 (57.1%) | 14/14 (100%) |
| Event | Phase 1b: 100 mg LY2940680 + C + E | Phase 1b: 200 mg LY2940680 + C + E | Phase 1b: 400 mg LY2940680 + C + E |
|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 2/6 | 1/6 | 0/14 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/6 | 2/6 | 0/14 |
| PneumoniaInfections and infestations | 1/6 | 0/6 | 3/14 |
| AnaemiaBlood and lymphatic system disorders | 0/6 | 1/6 | 0/14 |
| NeutropeniaBlood and lymphatic system disorders | 1/6 | 0/6 | 1/14 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/6 | 0/6 | 0/14 |
| Ventricular extrasystolesCardiac disorders | 0/6 | 1/6 | 0/14 |
| EnterocolitisGastrointestinal disorders | 1/6 | 0/6 | 0/14 |
| NauseaGastrointestinal disorders | 0/6 | 1/6 | 0/14 |
| PancreatitisGastrointestinal disorders | 0/6 | 1/6 | 0/14 |
| Event | Phase 1b: 100 mg LY2940680 + C + E | Phase 1b: 200 mg LY2940680 + C + E | Phase 1b: 400 mg LY2940680 + C + E |
|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 5/6 | 5/6 | 7/14 |
| FatigueGeneral disorders | 4/6 | 3/6 | 11/14 |
| NauseaGastrointestinal disorders | 2/6 | 4/6 | 10/14 |
| ConstipationGastrointestinal disorders | 4/6 | 1/6 | 8/14 |
| VomitingGastrointestinal disorders | 2/6 | 4/6 | 5/14 |
| Oedema peripheralGeneral disorders | 1/6 | 4/6 | 2/14 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 4/6 | 2/6 | 6/14 |
| DysgeusiaNervous system disorders | 4/6 | 4/6 | 8/14 |
| AnaemiaBlood and lymphatic system disorders | 2/6 | 3/6 | 8/14 |
| ThrombocytopeniaBlood and lymphatic system disorders | 3/6 | 3/6 | 8/14 |
All participants who received at least one dose of study drug.
| Age, Continuous(years) | Phase 1b: 100 mg LY2940680 + C +E | Phase 1b: 200 mg LY2940680 + C + E | Phase 1b: 400 mg LY2940680 + C + E | Total |
|---|---|---|---|---|
| Mean | 64.3 ± 9.35 | 64.8 ± 11.96 | 60.2 ± 12.19 | 62.2 ± 11.33 |
| Sex: Female, Male(Participants) | Phase 1b: 100 mg LY2940680 + C +E | Phase 1b: 200 mg LY2940680 + C + E | Phase 1b: 400 mg LY2940680 + C + E | Total |
|---|---|---|---|---|
| Female | 3 | 3 | 7 | 13 |
| Male | 3 | 3 | 7 | 13 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1b: 100 mg LY2940680 + C +E | Phase 1b: 200 mg LY2940680 + C + E | Phase 1b: 400 mg LY2940680 + C + E | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 1 |
| Not Hispanic or Latino | 6 | 5 | 14 | 25 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Phase 1b: 100 mg LY2940680 + C +E | Phase 1b: 200 mg LY2940680 + C + E | Phase 1b: 400 mg LY2940680 + C + E | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 1 | 3 |
| White | 6 | 3 | 13 | 22 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 |
| Region of Enrollment(participants) | Phase 1b: 100 mg LY2940680 + C +E | Phase 1b: 200 mg LY2940680 + C + E | Phase 1b: 400 mg LY2940680 + C + E | Total |
|---|---|---|---|---|
| United States | 5 | 5 | 10 | 20 |
| United Kingdom | 1 | 1 | 4 | 6 |
Plan to share: Yes — Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com. This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.
No publications or documents are linked to this record.
The record gives a start of Jan 2013, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2018, 3 years 10 months after primary completion. A results delay was requested in May 2015.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: LY2940680